The potential role of statins in pneumonia

Brandy Nakashima, Marcos Restrepo, Antonio R Anzueto, Eric M. Mortensen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalCurrent Respiratory Medicine Reviews
Volume6
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pneumonia
Hospitalization
Communicable Diseases
Human Influenza
Cause of Death
Research

Keywords

  • HMG-CoA reductase inhibitor
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The potential role of statins in pneumonia. / Nakashima, Brandy; Restrepo, Marcos; Anzueto, Antonio R; Mortensen, Eric M.

In: Current Respiratory Medicine Reviews, Vol. 6, No. 3, 2010, p. 155-161.

Research output: Contribution to journalArticle

Nakashima, Brandy ; Restrepo, Marcos ; Anzueto, Antonio R ; Mortensen, Eric M. / The potential role of statins in pneumonia. In: Current Respiratory Medicine Reviews. 2010 ; Vol. 6, No. 3. pp. 155-161.
@article{e7461f4d13cd4e708c1c924f55a8d56e,
title = "The potential role of statins in pneumonia",
abstract = "Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.",
keywords = "HMG-CoA reductase inhibitor, Pneumonia",
author = "Brandy Nakashima and Marcos Restrepo and Anzueto, {Antonio R} and Mortensen, {Eric M.}",
year = "2010",
doi = "10.2174/157339810791526193",
language = "English (US)",
volume = "6",
pages = "155--161",
journal = "Current Respiratory Medicine Reviews",
issn = "1573-398X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The potential role of statins in pneumonia

AU - Nakashima, Brandy

AU - Restrepo, Marcos

AU - Anzueto, Antonio R

AU - Mortensen, Eric M.

PY - 2010

Y1 - 2010

N2 - Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.

AB - Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.

KW - HMG-CoA reductase inhibitor

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=77958181360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958181360&partnerID=8YFLogxK

U2 - 10.2174/157339810791526193

DO - 10.2174/157339810791526193

M3 - Article

AN - SCOPUS:77958181360

VL - 6

SP - 155

EP - 161

JO - Current Respiratory Medicine Reviews

JF - Current Respiratory Medicine Reviews

SN - 1573-398X

IS - 3

ER -